Our preliminary results, therefore, suggest that glutaminase Ftrcould be used as prognostic markers in early-stage disease to predict patient outcome, and this warrants further validation in external DCIS cohorts. The gene discussed is GLS; the disease is ductal breast carcinoma in situ.